Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Post by wildbird1on Dec 21, 2022 12:35pm
343 Views
Post# 35184928

Has to be over 60%CR...

Has to be over 60%CR...I am one of the very few people on this board that come up with a CR% over 60% in Dec 2022, for the first 25 patients.
My Dec 12,2022  post was 71%CR/29 patients for the BTD application in Dec 2022.

Let"s me explain why the CR% has to be over 60%CR in Dec 2022.

PressRelease May 29,2020.
3) Breakthrough Therapy Designation, TLT said..."Continuing the FDA conference call, it was further discussed and agreed that Theralase would potentially be eligible for BTD and/or AA, if Theralase can demonstrate clinically significant results (high safety profile and high efficacy response), similar to the safety and efficacy results observed in the Phase 1b NMIBC clinical study(high safety profile and 67%CR) at an interim analysis of approximately 20 to 25 patients enrolled and successfully treated".

The most important word is "similar" to the 67%CR, for me similar is anything between 60-70%CR at 450 days.

Important note: It doesn't say, TLT will apply for BTD approval in Dec 2022 with a 30-40-45% CR%, NO! What is clearly stated is that TLT need a CR% that is at least over 60%CR(similar to 67%CR) to apply for BTD in Dec 2022.
The above mean that if TLT does apply for BTD in Dec 2022, the CR% on 25 patients at 450 days has to be over 60%CR(or the agreement with the FDA is invalidated).

Take the time to reread the May 29,2020 PressRelease, and if nobody can prove me wrong on this one, my over 60%CR in Dec 2022 stand. And if my over 60%CR% stand, it can only mean that TLT is heading for a very big deal with a big Pharma in 2023.



<< Previous
Bullboard Posts
Next >>